You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
An Oral Galectin Inhibitor in COVID-19—A Phase II Randomized Controlled Trial
|
|---|---|
| Published in |
Vaccines, March 2023
|
| DOI | 10.3390/vaccines11040731 |
| Pubmed ID | |
| Authors |
Alben Sigamani, Kevin H. Mayo, Michelle C. Miller, Hana Chen-Walden, Surendar Reddy, David Platt |
X Demographics
The data shown below were collected from the profiles of 976 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 92 | 9% |
| Germany | 25 | 3% |
| Canada | 22 | 2% |
| United Kingdom | 22 | 2% |
| Australia | 15 | 2% |
| Spain | 4 | <1% |
| France | 4 | <1% |
| Switzerland | 3 | <1% |
| Netherlands | 3 | <1% |
| Other | 32 | 3% |
| Unknown | 754 | 77% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 880 | 90% |
| Scientists | 45 | 5% |
| Practitioners (doctors, other healthcare professionals) | 31 | 3% |
| Science communicators (journalists, bloggers, editors) | 20 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 10 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Professor | 2 | 20% |
| Lecturer | 1 | 10% |
| Student > Ph. D. Student | 1 | 10% |
| Student > Master | 1 | 10% |
| Unknown | 5 | 50% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 2 | 20% |
| Nursing and Health Professions | 2 | 20% |
| Medicine and Dentistry | 1 | 10% |
| Unknown | 5 | 50% |
Attention Score in Context
This research output has an Altmetric Attention Score of 617. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 May 2024.
All research outputs
#38,144
of 26,210,036 outputs
Outputs from Vaccines
#32
of 4,576 outputs
Outputs of similar age
#1,019
of 429,805 outputs
Outputs of similar age from Vaccines
#1
of 312 outputs
Altmetric has tracked 26,210,036 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,576 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 28.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 429,805 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 312 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.